AG-348
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pyruvate Kinase Deficiency
Conditions
Pyruvate Kinase Deficiency, Anemia, Hemolytic
Trial Timeline
Jun 26, 2018 → Nov 12, 2020
NCT ID
NCT03559699About AG-348
AG-348 is a phase 3 stage product being developed by Agios Pharmaceuticals for Pyruvate Kinase Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT03559699. Target conditions include Pyruvate Kinase Deficiency, Anemia, Hemolytic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04000165 | Phase 1 | Completed |
| NCT03692052 | Phase 2 | Active |
| NCT03559699 | Phase 3 | Completed |
| NCT02476916 | Phase 2 | Completed |
Competing Products
9 competing products in Pyruvate Kinase Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 1 | 28 |
| Mitapivat + Mitapivat-matching placebo | Agios Pharmaceuticals | Phase 3 | 72 |
| Mitapivat + Mitapivat-matching placebo | Agios Pharmaceuticals | Phase 3 | 72 |
| Mitapivat | Agios Pharmaceuticals | Phase 3 | 72 |
| Placebo + AG-348 | Agios Pharmaceuticals | Phase 3 | 72 |
| Mitapivat | Agios Pharmaceuticals | Approved | 80 |
| AG-348 | Agios Pharmaceuticals | Phase 2 | 47 |
| RP-L301 | Rocket Pharmaceuticals | Phase 1 | 25 |
| RP-L301 | Rocket Pharmaceuticals | Phase 2 | 44 |